Updating results

1084 results

Sort: Relevance | Date

Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)

Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis (RRMS/MS) in adults

Technology appraisal guidance Published January 2014 Last updated June 2014

Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

Evidence-based recommendations on aflibercept (Zaltrap) with FOLFIRI for metastatic colorectal cancer that has progressed after oxaliplatin

Technology appraisal guidance Published March 2014

Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)

Evidence-based recommendations on inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)

Technology appraisal guidance Published March 2002

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab…

Technology appraisal guidance Published January 2016

Ocriplasmin for treating vitreomacular traction (TA297)

Evidence-based recommendations on ocriplasmin (Jetrea) for treating vitreomacular traction in adults

Technology appraisal guidance Published October 2013

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema after prior therapy

Technology appraisal guidance Published November 2013

Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

Evidence-based recommendations on peginterferon alfa and ribavirin (Pegasys) for treating chronic hepatitis C in children and young people

Technology appraisal guidance Published November 2013

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

Evidence-based recommendations on vinflunine (Javlor) for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

Technology appraisal guidance Published January 2013

Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) (TA270)

NICE is unable to make a recommendation about the use in the NHS of decitabine for the treatment of acute myeloid leukaemia because no evidence...

Technology appraisal guidance Published December 2012

Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)

Technology appraisal guidance Published November 2012

Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)

Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)

Technology appraisal guidance Published July 2014

Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)

Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure

Technology appraisal guidance Published June 2014

Alteplase for treating acute ischaemic stroke (TA264)

Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke (AIS)

Technology appraisal guidance Published September 2012

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published August 2012

Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

Evidence-based recommendations on bortezomib (Velcade) for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell..

Technology appraisal guidance Published April 2014

Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293)

Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)

Technology appraisal guidance Published July 2013 Last updated October 2018

Mirabegron for treating symptoms of overactive bladder (TA290)

Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder

Technology appraisal guidance Published June 2013

Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)

Evidence-based recommendations on total hip replacement and resurfacing arthroplasty for treating end-stage arthritis of the hip

Technology appraisal guidance Published February 2014

Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia

Technology appraisal guidance Published November 2013

Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)

Evidence-based recommendations on the use of fludarabine for B-cell chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published September 2001

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance Published June 2013

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

Evidence-based recommendations on bevacizumab (Avastin) in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

Technology appraisal guidance Published May 2013

Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) (TA281)

NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks

Technology appraisal guidance Published April 2013

Omalizumab for treating severe persistent allergic asthma (TA278)

Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma

Technology appraisal guidance Published April 2013

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275)

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)

Technology appraisal guidance Published February 2013

Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)

NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...

Technology appraisal guidance Published January 2013

Ranibizumab for treating diabetic macular oedema (TA274)

Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema

Technology appraisal guidance Published February 2013

Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)

Evidence-based recommendations on gefitinib (Iressa) for the first-line treatment of advanced or metastatic non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published July 2010

Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

Evidence-based recommendations on human growth hormone (somatropin) for treating growth failure in children

Technology appraisal guidance Published May 2010

Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma (tumours/cancer)

Technology appraisal guidance Published February 2010

Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating Crohn's disease in adults

Technology appraisal guidance Published May 2010

Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)

Evidence-based recommendations on spinal cord stimulation (SCS) for chronic pain of neuropathic or ischaemic origin in adults

Technology appraisal guidance Published October 2008

Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir, Symmetrel) and zanamivir (Relenza) to prevent influenza (flu)

Technology appraisal guidance Published September 2008

Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for the prevention of venous thromboembolism after hip or knee replacement surgery

Technology appraisal guidance Published September 2008

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for the treatment of age-related macular degeneration (AMD)

Technology appraisal guidance Published August 2008 Last updated May 2012

Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation (AF)

Technology appraisal guidance Published August 2010 Last updated December 2012

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

Evidence-based recommendations on adalimumab, etanercept, infliximab, rituximab and abatacept for treating rheumatoid arthritis after failure of a TNF inhibitor

Technology appraisal guidance Published August 2010

Capecitabine for the treatment of advanced gastric cancer (TA191)

Evidence-based recommendation on capecitabine (Xeloda) for treating advanced (inoperable) gastric cancer (stomach cancer)

Technology appraisal guidance Published July 2010

Infliximab for acute exacerbations of ulcerative colitis (TA163)

Evidence-based recommendations on infliximab (Remicade) for acute exacerbations of ulcerative colitis in adults

Technology appraisal guidance Published December 2008

Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance Published October 2008 Last updated February 2018

Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

Evidence-based recommendations on amantadine (Lysovir, Symmetrel), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza (flu)

Technology appraisal guidance Published February 2009

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

Evidence-based recommendations on rivaroxaban (Xarelto) for the prevention of venous thromboembolism after total hip or knee replacement in adults

Technology appraisal guidance Published April 2009

Febuxostat for the management of hyperuricaemia in people with gout (TA164)

Evidence-based recommendations on febuxostat (Adenuric) for the management of hyperuricaemia in people with gout

Technology appraisal guidance Published December 2008

Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours (cancer of stomach/digestive system)

Technology appraisal guidance Published September 2009

Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published July 2009

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma

Technology appraisal guidance Published August 2009

Telbivudine for the treatment of chronic hepatitis B (TA154)

Evidence-based recommendations on telbivudine (Sebivo) for the treatment of chronic hepatitis B

Technology appraisal guidance Published August 2008

Entecavir for the treatment of chronic hepatitis B (TA153)

Evidence-based recommendations on entecavir (Baraclude) for the treatment of chronic hepatitis B

Technology appraisal guidance Published August 2008

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

Technology appraisal guidance Published July 2008

Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)

NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the

Technology appraisal guidance Published June 2008